BCRX vs HCM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BCRX · BioCryst Pharmaceuticals$7.69 ▲ 0.79%
HCM · Hutchmed (China)$15.16 ▲ 6.76%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BCRX +6.8%
- HCM +0.5%
Head to head
| Metric | BCRX | HCM |
|---|---|---|
| Price | $7.69 | $15.16 |
| Change today | ▲ 0.79% | ▲ 6.76% |
| Market cap | $1.98B | $2.64B |
| Return, 3 months | -21.8% | +20.8% |
| Return, year to date | -1.4% | +13.7% |
| Return, 1 year | +8.5% | +1.4% |
| P/E (TTM) | -6.0 | 189.5 |
| P/B | -5.0 | 2.1 |
| P/E percentile vs own 5y | 69th | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +33.6% | +37.3% |
| Net profit growth (YoY) | +1,441.7% | -81.3% |
| Gross margin | 97.8% | 41.6% |
| Operating margin | -33.3% | -5.7% |
| Net margin | -40.9% | 3.3% |
| Return on equity | – | 1.4% |
| Analyst target vs. price | +154.5% | +20.4% |
| Analyst buy share | 71% | 100% |
| RSI (14) | 41 | 63 |
| 30-day volatility | 45.1% | 44.6% |
| Max drawdown, 1 year | -31.3% | -37.8% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HCM is the largest of the group by market value.
- BCRX has returned the most over the past year.
- BCRX carries the lowest trailing P/E.
- HCM is growing revenue fastest.
- HCM keeps the most profit per dollar of sales.
- HCM has been the calmest stock over the last 30 days.